Home/Investors/F-Prime Capital F-Prime Capital
Biotech Investor · 16 portfolio companies
Portfolio Companies
| Company | Stage | Valuation | Focus |
|---|
| Laurus Labs | Commercial | $663.3B | HIV/AIDS, Oncology |
| Allorion Therapeutics | preclinical | — | Oncology, Immunology |
| ARTBIO | Phase 2 | — | Oncology |
| CHARM Therapeutics | preclinical | — | Oncology |
| Owkin | Approved | — | Oncology, Glioblastoma |
| Atalanta Therapeutics | preclinical | — | Neuroscience, Rare Disease |
| Avalyn Pharmaceuticals | Phase 2 | — | Pulmonary Fibrosis, Interstitial Lung Diseases |
| OrsoBio | Phase 2 | — | Metabolic Diseases, Liver Diseases |
| RIGImmune | Pre-clinical | — | Asthma, Cystic Fibrosis |
| AviadoBio | Phase 1 | — | Neurodegenerative Diseases, Ophthalmology |
| Leyden Labs | Phase 1 | — | Infectious Disease, Respiratory Diseases |
| Sciwind Biosciences | phase-2 | — | Metabolic |
| Maven Bio | preclinical | — | Oncology, Immunology |
| Alveus Therapeutics | preclinical | — | Respiratory, Pulmonology |
| Aera Therapeutics | preclinical | — | Gene Therapy, Rare Diseases |
| Alebund Pharmaceutical | phase-2 | — | Metabolic, Rare Disease |